345 related articles for article (PubMed ID: 17197368)
1. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
Youdim MB; Amit T; Bar-Am O; Weinreb O; Yogev-Falach M
Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
[TBL] [Abstract][Full Text] [Related]
2. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
Yogev-Falach M; Bar-Am O; Amit T; Weinreb O; Youdim MB
FASEB J; 2006 Oct; 20(12):2177-9. PubMed ID: 16935943
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
Youdim MB; Weinstock M
Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
[TBL] [Abstract][Full Text] [Related]
5. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
Youdim MB
Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
[TBL] [Abstract][Full Text] [Related]
6. Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs.
Weinreb O; Mandel S; Bar-Am O; Yogev-Falach M; Avramovich-Tirosh Y; Amit T; Youdim MB
Neurotherapeutics; 2009 Jan; 6(1):163-74. PubMed ID: 19110207
[TBL] [Abstract][Full Text] [Related]
7. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Curr Drug Targets; 2012 Apr; 13(4):483-94. PubMed ID: 22280345
[TBL] [Abstract][Full Text] [Related]
8. The neuroprotective mechanism of action of the multimodal drug ladostigil.
Weinreb O; Amit T; Bar-Am O; Yogev-Falach M; Youdim MB
Front Biosci; 2008 May; 13():5131-7. PubMed ID: 18508575
[TBL] [Abstract][Full Text] [Related]
9. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
Youdim MB
Exp Neurobiol; 2013 Mar; 22(1):1-10. PubMed ID: 23585716
[TBL] [Abstract][Full Text] [Related]
10. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
Bar-Am O; Amit T; Weinreb O; Youdim MB; Mandel S
J Alzheimers Dis; 2010; 21(2):361-71. PubMed ID: 20555137
[TBL] [Abstract][Full Text] [Related]
11. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Youdim MB; Amit T; Bar-Am O; Weinstock M; Yogev-Falach M
Ann N Y Acad Sci; 2003 May; 993():378-86; discussion 387-93. PubMed ID: 12853332
[TBL] [Abstract][Full Text] [Related]
12. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats.
Bar-Am O; Weinreb O; Amit T; Youdim MB
J Mol Neurosci; 2009 Feb; 37(2):135-45. PubMed ID: 18751929
[TBL] [Abstract][Full Text] [Related]
13. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
Youdim MB; Bar Am O; Yogev-Falach M; Weinreb O; Maruyama W; Naoi M; Amit T
J Neurosci Res; 2005 Jan 1-15; 79(1-2):172-9. PubMed ID: 15573406
[TBL] [Abstract][Full Text] [Related]
14. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro.
Bar-Am O; Amit T; Youdim MB
J Neurochem; 2007 Oct; 103(2):500-8. PubMed ID: 17635668
[TBL] [Abstract][Full Text] [Related]
15. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline.
Yogev-Falach M; Amit T; Bar-Am O; Weinstock M; Youdim MB
FASEB J; 2002 Oct; 16(12):1674-6. PubMed ID: 12206996
[TBL] [Abstract][Full Text] [Related]
16. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
Youdim MB; Kupershmidt L; Amit T; Weinreb O
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer's Disease.
Uddin MS; Kabir MT; Rahman MH; Alim MA; Rahman MM; Khatkar A; Al Mamun A; Rauf A; Mathew B; Ashraf GM
Curr Pharm Des; 2020; 26(37):4690-4698. PubMed ID: 32250219
[TBL] [Abstract][Full Text] [Related]
18. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity.
Weinreb O; Bar-Am O; Amit T; Drigues N; Sagi Y; Youdim MB
Chem Biol Interact; 2008 Sep; 175(1-3):318-26. PubMed ID: 18598687
[TBL] [Abstract][Full Text] [Related]
19. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
Zheng H; Amit T; Bar-Am O; Fridkin M; Youdim MB; Mandel SA
J Alzheimers Dis; 2012; 30(1):1-16. PubMed ID: 22387411
[TBL] [Abstract][Full Text] [Related]
20. A novel anti-Alzheimer's disease drug, ladostigil neuroprotective, multimodal brain-selective monoamine oxidase and cholinesterase inhibitor.
Weinreb O; Amit T; Bar-Am O; Youdim MB
Int Rev Neurobiol; 2011; 100():191-215. PubMed ID: 21971009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
